The immunophenotyping of the lymphocytes, especially CD4+ T cells from peripheral blood is being used to assess the extent of immune dysfunction in the primary and secondary immunodeficiency, chronic infectious diseases and various cancers such as Hodgkin's disease, lymphoma, etc.
Decreased CD3+ and CD4+ T cells and increased IgE levels were more frequently observed in the Hodgkin's disease survivors with recurrent infections.
The first phase occurs during primary HIV infection and the early part of chronic infection when there is substantial depletion of memory (CCR5+) CD4+ T cells
and disruption of the structure and function of secondary lymphoid tissues, especially the gut-associated lymphoid tissue (GALT) of the intestinal tract [1-4].
The vaccinated animals had good CTL (cytotoxic T lymphocyte) response after infection, stable CD4+ counts (T-cell counts), and CD4+ T cells
that responded specifically to the infecting virus.
Latent infection of CD4+ T cells
provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
Enumeration of CD4+ T cells
constitutes an essential biological indicator in the clinical follow up of patients infected with HIV-1.
A single cycle (3 subcutaneous injections) induced a rapid and sustained increase of CD4+ and CD8+ T cells, with most patients treated with 20 og/kg of CYT107 reaching CD4+ T cells
counts > 500 cells/oL at W12
The primary endpoint was to determine whether the LHRH agonist could induce renewed thymic function and output of new naive CD4+ T cells
(which are required for all immune responses), compared to similar patients not receiving the LHRH.
REMUNE(R)'s effect on immune reconstitution as further evidenced by an augmented serum concentration of IL-7 and increases in naive CD4+ T cells
suggests a possible mode of action via stimulation of thymus function.
Data from three separate study sites showed that results obtained using the Guava EasyCD4(TM) and EasyCD8(TM) Assays for the enumeration of Human CD4+ T cells
and CD8+ T cells showed excellent correlation with the standard, clinically approved BD MultiTEST(TM) (flow cytometry) assay.
CD4+ T cells
not only have the ability to mount a direct offense against cancerous or infected cells, but also help orchestrate the activity of other cells of the immune system.
The study conducted in Spain was a multicenter, double-blind, placebo-controlled, randomized trial of 243 antiviral naive patients with chronic HIV infection with CD4+ T cells
between 300-700 cells/ml.